PetVivo Holdings, Inc. (PETV): Business Model Canvas [Dec-2025 Updated]

You're digging into the mechanics of PetVivo Holdings, Inc., trying to see if their strategic pivot into AI actually lines up with the hard numbers, and honestly, that's smart analysis. As someone who has mapped out company strategies for over two decades, I can tell you PetVivo Holdings, Inc. is defintely making moves, leaning on their core veterinary devices while launching the Agentic Pet AI platform. Their fiscal 2025 story shows a record $1.1 million in net revenue, supported by a very healthy 87.8% gross margin, but they're still investing heavily in R&D and sales to push products like Spryng. Let's break down the nine blocks of their Business Model Canvas-from their exclusive AI license to how 85% of their revenue came from distributors-so you can see the whole picture below.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Key Partnerships

You're mapping out the strategic alliances PetVivo Holdings, Inc. is using to scale its medical device and new AI offerings; these partnerships are defintely critical for reaching the veterinary market.

Exclusive 10-year AI license with Digital Landia Holding Corp.

This exclusive, 10-year white-label licensing agreement, finalized in October 2025, underpins the AgenticPet AI Framework, which powers PetVivo's B2B veterinary-practice platform launching in Q1 2026. The deal was supported by a strategic investment that included 1 million restricted shares of PetVivo Holdings, Inc.. The technology itself is built on 5 patent-pending innovations and utilizes 9 specialized diagnostic agents. The financial implications for veterinary practices are significant, as the AI aims to reduce client acquisition costs by 90% to 98%.

Here's a quick look at the projected cost savings for clinics using the AI platform:

The shift to this AI Software-as-a-Service (SaaS) model is key, moving PetVivo from device margins of 30-40% to potential SaaS margins of 80-90%. For consumers, the B2C Agentic Pet app offers premium diagnostics for $9.99/month.

Master Services Agreement with PiezoBioMembrane for biomaterial R&D

PetVivo Holdings, Inc. has a Master Services Agreement in place with PiezoBioMembrane to advance biomaterial Research and Development. No specific financial figures related to this agreement were publicly detailed as of late 2025.

National distribution agreements with Vedco and Clipper Distributing

The distribution network was strengthened with new partnerships with Vedco Inc. and Clipper Distributing, LLC, announced in January 2025. These partners supply products to major national veterinary distribution entities. Distributor sales were a major component of the company's recent performance, totaling $237,000 in the second quarter of fiscal year 2026, which accounted for 75% of the total Q2 FY2026 revenue of $303,000. Since the introduction of Spryng® with OsteoCushion® Technology, it has been used by over 1,000 veterinary clinics across all 50 states.

Vendor Partner Agreement with Veterinary Growth Partners

In October 2025, PetVivo Animal Health, Inc. entered a Vendor Partner Agreement with Veterinary Growth Partners (VGP). VGP is a management services organization (MSO) that supports its network by offering practice management and vendor relationships. VGP serves more than 7,300 veterinary members across the United States and committed to actively promoting Spryng® and PrecisePRP® to this network.

International distributors in Mexico, the UK, and Nupsala Limited

The company is actively expanding its geographic footprint through distribution agreements. PetVivo Holdings, Inc. announced a distribution agreement with Nupsala Limited in August 2025. Furthermore, the company expanded its operations into Mexico and the UK during the second quarter of fiscal year 2026, which ended September 30, 2025. The presence in Mexico includes new international clinics served by existing distributors.

Finance: draft 13-week cash view by Friday.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Key Activities

You're looking at the core actions PetVivo Holdings, Inc. is taking to drive value right now, late in 2025. It's a mix of established medical device sales and a massive pivot into AI services.

Manufacturing and commercialization of Spryng and PrecisePRP

The company focuses on getting its two main products, Spryng with OsteoCushion Technology and PrecisePRP, into veterinary hands. Spryng, the lead product, has been used by more than 800 veterinary clinics across all 50 states since its introduction in the fall of 2021. The newer PrecisePRP product line contributed to a 51% year-over-year increase in total revenue for the fiscal second quarter of 2026, reaching $303,000. The first half of fiscal year 2026 saw revenues surpass $600,000, which was an 85% increase over the same period last year. To be fair, the margin profile is shifting; traditional device sales historically generated 30-40% margins, but the new PrecisePRP product carries a smaller margin.

Research and development of new functional biomaterials

Research and development activities are being managed alongside cost-cutting measures. For the fiscal year 2025 ending March 31, 2025, PetVivo Holdings, Inc. cut operating expenses by 21% to $9.1 million compared to fiscal year 2024, with reduced research and development costs being a contributing factor. More recently, operating expenses for the second fiscal quarter of 2026 decreased by 3% to $2.3 million from $2.4 million in the year-ago quarter, again citing reduced research and development costs. The company also has strategic partnerships mentioned, including one with PiezoBioMembrane.

Expanding the nationwide and international distributor network

Expanding the network is a major driver of the current revenue stream. For the full fiscal year 2025, distributor network sales totaled $958,000, making up 86% of the record $1.1 million in total revenue. In the most recent reported quarter, fiscal Q2 2026, distributor network sales reached $237,000, which was 75% of total revenues for that quarter and represented a 35% increase over the same year-ago quarter. This expansion is both domestic and international, with sales ramping up in Mexico and operations kicking off in the U.K.. The network includes established relationships with over 1,000 clinics and a vendor partner agreement with Veterinary Growth Partners (VGP), which supports more than 7,300 veterinary members.

Sales and marketing to veterinary professionals

Sales and marketing efforts are being ramped up, particularly to support the PrecisePRP rollout, which impacts short-term costs. The operating loss for the second fiscal quarter of 2026 increased by 12% to $2.1 million, which was attributed to increased sales and marketing expenses related to the new PrecisePRP product line. The company has also realigned and expanded its sales force to focus on the larger companion animal market, moving beyond its initial strong focus on the equine market.

Developing and launching the Agentic Pet AI platform

This represents a significant new key activity following a major licensing agreement. PetVivo Holdings, Inc. entered an exclusive 10-year white-label licensing agreement in October 2025 for the Agentic Pet AI technology. The technology is claimed to reduce client acquisition costs by 90-98%, potentially dropping costs from $50 - $150+ per client to just $1.50 - $5.00 per targeted outreach. The platform, PetVivo.ai, launched commercially in November 2025, delivering a customer acquisition cost of $42.53, which is a 50-89% reduction compared to the typical $80-$400 spent by practices. This AI platform is expected to operate on a high-margin Software-as-a-Service (SaaS) model with projected 80-90% margins. The company is targeting a dual launch of the B2C and B2B platforms in Q1 2026, with pre-launch registration starting January 2026. This move positions PetVivo Holdings, Inc. to enter a US veterinary AI market valued at $4.9 billion, with over 30,000+ addressable clinics.

Here's a quick look at the financial context surrounding these activities as of late 2025:

The shift to the AI platform is defintely a major new operational focus, moving PetVivo Holdings, Inc. toward a recurring revenue model with projected 80-90% margins. Finance: draft 13-week cash view by Friday.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Key Resources

You're looking at the core assets that power PetVivo Holdings, Inc.'s operations as of late 2025. These aren't just line items; they are the proprietary tech and established reach that drive the entire business model.

Intellectual Property Foundation

The company's technology is locked down by a significant portfolio of intellectual property. This IP protects the core innovation behind their product line, which is crucial for maintaining a competitive moat, especially in the medical device space.

• Portfolio of twelve patents.
• Protection extended by six trade secrets covering biomaterials, processes, and methods of use.

Proprietary Technology Assets

The primary tangible resource is the Proprietary OsteoCushion biomaterial technology, which forms the basis of their lead product, Spryng®. This technology is an intra-articular injectable device designed to manage lameness and osteoarthritis in animals.

Furthermore, PetVivo Holdings, Inc. secured the Exclusive B2B rights to Agentic Pet AI technology through an exclusive 10-year white-label licensing agreement with Digital Landia Holding Corp, announced in October 2025. This AI framework, which is production-ready for a Q1 2026 commercial launch, features nine specialized AI agents designed to deliver real-time, data-driven insights for veterinary practices.

Distribution and Market Access Network

The established network represents significant human capital and market penetration. The core product, Spryng®, has achieved broad adoption across the United States.

• Spryng® has been administered by more than 1,200 veterinary clinics across all 50 states since its market introduction in late 2021.
• Strategic alliance with Veterinary Growth Partners (VGP) grants access to an expansive member network of more than 7,300 veterinary hospital clinic members across the U.S. for promoting Spryng® and PrecisePRP™.

Financial Liquidity Snapshot (As of Fiscal Year-End March 31, 2025)

You need to know the cash position at the end of the fiscal year to gauge immediate operational runway before subsequent financing events. Here's the quick math on the balance sheet items relevant to the required date, though note that later financing strengthened this position to $768,000 by September 30, 2025.

The fiscal year 2025 results show that distributor sales accounted for 85% of the total $1.1 million in record revenues, indicating a heavy reliance on the established distribution channel for product movement.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Value Propositions

You're looking at the core benefits PetVivo Holdings, Inc. is delivering to its customers-primarily veterinary practices and, by extension, pet owners. These aren't just features; they are quantified improvements to the economics and quality of care in the animal health space.

Spryng: Single-injection, long-lasting joint pain relief for animals.

This is the flagship offering, the intra-articular injectable medical device using OsteoCushion Technology. It's designed to manage lameness and joint pain from conditions like osteoarthritis. As of June 30, 2025, Spryng had been administered by more than 1,000 veterinary clinics across all 50 states since its 2021 introduction. The product line contributed significantly to the record Fiscal Year 2025 revenue of $1.1 million, which was a 17% increase year-over-year. The gross margin on the core device business in that fiscal year stood at a strong 87.8%.

PrecisePRP: First-in-class, off-the-shelf platelet-rich plasma product.

PrecisePRP, a leucoreduced, allogeneic, pooled, freeze-dried PRP, is a key growth driver, especially in the companion animal segment. Its introduction helped push Fiscal Q2 2026 revenues up 51% year-over-year to $303,000. To be fair, the introduction of this new product line, which carries a smaller margin than Spryng, caused the blended gross margin to dip to 72.6% in Q2 Fiscal 2026. Still, the company is building out inventory for this product to meet growing demand.

PetVivo.ai: Reduces veterinary client acquisition costs by 50-89%.

This is a major strategic pivot, moving into a high-margin Software-as-a-Service (SaaS) model with projected gross margins of 80-90%. Launched in late November 2025, the platform directly addresses the high cost veterinary practices face, which typically ranges from $80-$400 per new client. The platform was validated in a 50-practice beta program, showing clear economic advantages:

Here's the quick math: a 50-89% reduction in CAC is the headline value. The platform targets 30,000 U.S. practices, projecting an Annual Recurring Revenue (ARR) of $180 million by Year 3 if 5,000 practices adopt the service.

Innovative, non-pharmaceutical medical devices for lameness.

The value here is delivering medical device solutions that bypass the longer, more stringent regulatory path of pharmaceuticals. This strategy allows for an accelerated timeline to revenue. The company's portfolio includes two key products for joint afflictions:

• Spryng with OsteoCushion Technology, an intra-articular injectable.
• PrecisePRP, an off-the-shelf platelet-rich plasma product.

Accelerated time-to-market by leveraging human therapies for animal use.

PetVivo Holdings, Inc.'s strategy explicitly centers on this acceleration. The company pursues the development of novel human therapies for animal treatment in a capital and time efficient manner. This approach means veterinary medical devices enter the market significantly earlier than more stringently regulated biologics or pharmaceuticals. The company protects this approach with a portfolio of twenty-one patents covering biomaterials, products, and methods of use.

Finance: draft 13-week cash view by Friday.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Customer Relationships

You're looking at how PetVivo Holdings, Inc. is planning to build and keep its customer base as of late 2025, which is a fascinating mix of old-school sales and brand-new AI. The relationships here are clearly bifurcated between the traditional medical device channel and the new high-margin software channel.

Dedicated in-house sales force for direct engagement

The direct engagement model, which supports the medical device side, is still a core part of the strategy. We see evidence of this in the reported growth drivers. For instance, the revenue increase in the second quarter of fiscal year 2026 was attributed, in part, to the expansion of the company's in-house sales force. This force is crucial for driving adoption of products like Spryng with OsteoCushion Technology and the newer Precise PRP. While a specific headcount isn't public, the impact is clear: distributor sales increased by 35% to $237,000 in Q2 FY2026, representing 75% of total revenues, suggesting the direct sales team is effectively supporting and expanding that network.

Educational programs (RACE-Approved CE Courses) for veterinarians

Building trust with the veterinary community requires more than just a sales pitch; it demands education. PetVivo Holdings has been actively engaging this segment through industry events and formal learning. As recently as September 2025, PetVivo Animal Health expanded its veterinary education by announcing new RACE-Approved CE Courses focused on Osteoarthritis and Regenerative Therapies. You can see their commitment to this in their recent physical presence, too. They exhibited at the Texas Equine Veterinary Association 2025 Summer CE Symposium in Marble Falls, Texas, and also showed Precise PRP technology jointly with VetStem at the 2025 Fetch Kansas City Veterinary Conference in August. This hands-on, educational approach directly supports the relationship with the prescribing professional.

Automated, digital engagement via the B2B AI platform

This is where the relationship model shifts dramatically toward digital scalability, starting in late November 2025 with the launch of PetVivo.ai. This platform is designed to automate the most painful part of a veterinarian's relationship building: client acquisition. Here's the quick math on the value proposition for the vet clinic customer:

The platform uses a suite of nine AI Agents and is priced at $1,999/month for the Professional tier. This transition moves PetVivo Holdings from a traditional medical device margin structure of 30-40% to a high-margin AI Software-as-a-Service (SaaS) margin of 80-90%. The target is massive, aiming for 30,000 U.S. practices, with a Year 1 projection of $12M Annual Recurring Revenue based on 500 practices.

High-touch support for distributor network partners

The distributor network remains the primary revenue engine, demanding a high-touch relationship. In the fourth quarter of fiscal 2025, distributor network sales were responsible for 86% of the company's total revenue, following a 31% surge. Even in the subsequent quarter (Q2 FY2026), distributor sales were $237,000, making up 75% of the total. Supporting these partners involves ensuring product availability and navigating new markets, such as the expansion into Mexico and the U.K. via partners like Nupsila Limited. If onboarding takes 6-12 months for new products, as noted in one risk assessment, this high-touch support is defintely critical to keep the revenue flowing.

Building a defintely sticky two-sided platform ecosystem

Stickiness is engineered through long-term commitment and deep integration. For the AI platform, this is secured by an exclusive 10-year white-label licensing agreement with Digital Landia Holding Corp for the Agentic Pet AI technology. This long-term contract locks in the core technology relationship. Furthermore, the platform is designed to be sticky for the veterinary practice itself by delivering an exceptional 25:1 LTV/CAC ratio and a 1-month payback period, meaning the value delivered to the customer far outweighs the cost and time to see a return. The platform's success is directly tied to the vet's success in client acquisition.

• The AI platform targets a potential market of over 100,000 veterinary practices globally.
• The platform's economics validate the relationship by showing a 50-89% reduction in client acquisition costs.
• The company's total cash balance grew to $768,000 on September 30, 2025, providing resources to maintain these critical relationships.

Finance: draft 13-week cash view by Friday.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Channels

You're looking at how PetVivo Holdings, Inc. gets its products and services-like Spryng® with OsteoCushion™ Technology and the new PetVivo.ai-into the hands of veterinarians and animal owners as of late 2025. The strategy heavily leans on established third-party networks, but they are clearly building out direct and high-tech avenues too.

Nationwide animal health distributors (primary channel).

This is the engine room for PetVivo Holdings, Inc.'s current revenue. For the fiscal year ending June 30, 2025, sales through the distributor network accounted for a massive 85% of the total revenue, bringing in $958,000 of the total $1.1 million in revenue. This reliance on distributors is strategic for broad market penetration, especially given the addition of Vedco and Clipper Distributing in late 2024 to bolster the U.S. network. The momentum continued into the next fiscal period; for the second quarter of fiscal 2026 (ending September 30, 2025), distributor sales grew 35% year-over-year to $237,000, making up 75% of that quarter's total revenue.

Here's a look at the distributor revenue contribution:

Direct sales to independent veterinary clinics.

While distributors are the primary revenue driver, direct sales remain a key channel for adoption and relationship building. As of June 30, 2025, PetVivo Holdings, Inc. reached a milestone with Spryng® being utilized by over 1,000 veterinary clinics across all 50 states in the United States. It's worth noting that in the third quarter of fiscal 2025 (ending December 31, 2024), the company saw decreased direct sales as it actively transitioned focus toward the expanding distribution network, anticipating longer-term growth benefits from that channel.

International distributors for Mexico and the UK.

PetVivo Holdings, Inc. has actively moved into international distribution. The company entered the Mexican market through a distribution agreement with Eq Especialidades, with sales and marketing activities commencing on April 1, 2025. Furthermore, operations have launched in the UK through a partnership with Nupsala Group, a veterinary wholesaler, where the initial order has shipped and sales force education is scheduled to begin mid-January.

Key international channel activities:

• Agreement with Eq Especialidades for distribution throughout Mexico.
• Launch of operations in the UK with Nupsala Group.
• UK sales force training scheduled for mid-January.

B2B subscription platform for veterinary practices (PetVivo.ai).

This represents a major shift into a high-margin, recurring revenue stream. PetVivo.ai, an artificial intelligence platform, was launched to reduce veterinary client acquisition costs by 50-89% compared to the typical $80-$400 spent. The Professional tier is priced at $1,999/month. The platform targets 30,000 U.S. practices and over 100,000 globally. Beta testing showed a median acquisition of 47 new clients over 6 months. The company projects strong scaling potential, aiming for 500 practices in Year 1 for an estimated $12 million ARR (Annual Recurring Revenue), and 10,000 practices in Year 5 for an estimated $360 million ARR. This SaaS model carries projected gross margins of 80-90%, significantly higher than the historical 30-40% margins from traditional medical device sales.

Participation in major veterinary conferences.

Physical presence at industry events remains a channel for engagement and awareness. PetVivo Holdings, Inc. is scheduled to exhibit at the American Association of Equine Practitioners Convention on December 6-10, 2025. This type of event directly targets the equine segment of their customer base.

Finance: draft 13-week cash view by Friday.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Customer Segments

Companion animal veterinarians (dogs, cats).

The market for pet care now exceeds $150 billion annually. PetVivo Holdings, Inc. (PETV) serves this segment, with its lead product, Spryng with OsteoCushion Technology, used in more than 1,000 veterinary clinics across all 50 states as of the end of fiscal year 2025 (ended March 31, 2025). For the second quarter of fiscal year 2026 (ended September 30, 2025), the company reported total revenues of $303,000, with national distributor network sales reaching $237,000, which accounted for 75% of those total revenues. The company is actively broadening its focus from the equine market into the larger companion animal space.

Equine veterinarians and horse owners.

The company's initial focus included the equine market, where its Spryng product gained initial adoption. The fiscal year 2025 preliminary unaudited revenue was a record $1.1 million, driven in part by North American expansion and the distributor network, which contributed $958,000 or 86% of that total. The company continues to strengthen its platform with technologies for both horses and companion animals.

Veterinary practices seeking client acquisition and efficiency tools.

This segment is targeted by the new PetVivo.ai platform, which aims to transform the market by addressing high client acquisition costs. The platform targets 30,000 U.S. veterinary practices globally. The economics were validated in a beta program where the median practice acquired 47 new clients over 6 months. The projected Year 1 Annual Recurring Revenue (ARR) from an adoption of 500 practices is $12 million.

Pet parents (indirectly via the Agentic Pet B2C app).

Pet parents are reached indirectly through the B2B platform's lead generation and the upcoming Digital Landia's Agentic Pet B2C app. This demographic is significant, as Gen Z and Millennial pet parents make up 57% of all pet owners. The underlying Agentic Pet AI technology has the potential to deliver a 90% - 98% reduction in client acquisition costs for practices, lowering the cost to just $1.50 - $5.00 per targeted outreach when fully implemented.

Key customer base metrics include:

• Gen Z and Millennial pet parents comprise 57% of pet owners.
• The AI platform generated qualified leads at $3 each in beta.
• The median beta practice added 47 new clients in 6 months.
• Spryng usage covers over 1,000 veterinary clinics nationwide.
• FY2026 Q2 distributor sales accounted for 75% of total revenue.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Cost Structure

You're looking at the core expenses driving PetVivo Holdings, Inc.'s operations through fiscal year 2025. The cost structure is heavily weighted toward getting products like Spryng with OsteoCushion Technology and PrecisePRP into the market, but there's a clear trend toward efficiency in overhead.

Research and Development (R&D) Investment

PetVivo Holdings, Inc. shows a commitment to product development, evidenced by increased R&D spending in the fiscal year ending March 31, 2025. This investment supports ongoing clinical studies and the launch efforts for their lead products.

• R&D expenses for fiscal 2025 totaled $1,583,250.
• This was an increase from the $1,395,371 reported for fiscal 2024.

General and Administrative (G&A) and Sales & Marketing

The company has actively managed its fixed overhead costs. You see this clearly when comparing the nine-month results and the full-year figures. The strategic restructuring program is definitely showing up in the G&A line item.

For the nine months ending December 31, 2024, the General and Administrative expenses were reduced by $1 million. This was part of a larger cost reduction effort that also included a $1.2 million reduction in sales and marketing expenses for that nine-month period.

Looking at the full fiscal year 2025 results:

The full-year G&A reduction of over $1.8 million suggests the $1 million nine-month reduction was a significant driver.

Cost of Goods Sold (COGS) and Gross Margin

The Cost of Sales, which is the COGS component, remains relatively low, which is key to the profitability profile of the core product sales. This low cost base directly supports the high gross margin PetVivo Holdings, Inc. maintains.

• Cost of sales for fiscal 2025 was $137,677.
• This resulted in a high gross margin of 87.8% for fiscal year 2025.
• Gross profit for FY2025 climbed to $995,000.

Total Operating Expenses

When you aggregate all the operating costs-G&A, Sales & Marketing, and R&D-the company achieved a substantial reduction in its total operating expense base for fiscal 2025 compared to the prior year. This is a major factor in the improved operating loss.

The total operating expenses for fiscal 2025 were reported at $9.05 million. This figure represents a decrease of approximately 21% compared to the prior period, which directly contributed to the operating loss contracting by 24% to $8.1 million in fiscal 2025. The operating expenses breakdown for the full fiscal year 2025 was approximately:

Finance: draft 13-week cash view by Friday.

PetVivo Holdings, Inc. (PETV) - Canvas Business Model: Revenue Streams

You're looking at the core ways PetVivo Holdings, Inc. brings in cash right now, based on their latest full fiscal year results. It's all about product sales, but the structure of those sales is shifting, which is key for you to track.

The primary revenue sources for PetVivo Holdings, Inc. stem from the sales of their medical devices, specifically Spryng and PrecisePRP medical devices. These are the physical products moving through the sales channels.

Here is a breakdown of the key financial figures from the fiscal year 2025:

The reliance on the distributor channel is quite high, representing 85% of the total $1.1 million in revenue for fiscal 2025. That $958,000 from distributors shows where the current sales engine is running hardest. Still, you should watch the direct sales channel, as recent Q2 FY2026 data suggests a shift in the mix, with distributor sales making up 75% of the smaller quarterly revenue of $303,000 for that period ending September 30, 2025.

Looking ahead, PetVivo Holdings, Inc. is building out other potential revenue streams, though concrete numbers for late 2025 aren't fully realized yet. These are important for future valuation:

• Future B2B subscription fees for the AI platform (PetVivo.ai).
• Potential licensing revenue from proprietary biomaterial technology.

The company has made moves to secure these future streams. For instance, they entered a licensing agreement with Digital Landia Holding Corp to integrate AI technologies. Also, PetVivo Holdings, Inc. signed exclusive licensing agreements with VetStem, Inc., aiming to commercialize PrecisePRP®. These agreements signal a move toward recurring or upfront revenue components beyond just device sales.